Immunocore FY2027 EPS Forecast Increased by HC Wainwright

Immunocore Holdings plc (NASDAQ:IMCR) – Investment analysts at HC Wainwright boosted their FY2027 earnings estimates for shares of Immunocore in a report released on Friday, February 28th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of $1.10 per share for the year, up from their previous forecast of $1.04. HC Wainwright has a “Buy” rating and a $100.00 price objective on the stock. The consensus estimate for Immunocore’s current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Immunocore’s FY2028 earnings at $4.46 EPS and FY2029 earnings at $7.96 EPS.

A number of other equities research analysts also recently issued reports on the company. Needham & Company LLC reissued a “buy” rating and set a $71.00 price target on shares of Immunocore in a research report on Thursday, February 27th. Morgan Stanley reissued an “equal weight” rating and set a $35.00 target price (down from $74.00) on shares of Immunocore in a report on Friday, December 13th. Finally, Mizuho downgraded Immunocore from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $72.00 to $38.00 in a research note on Monday, November 11th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $65.64.

Immunocore Stock Performance

Shares of NASDAQ:IMCR opened at $28.88 on Monday. Immunocore has a 12-month low of $27.69 and a 12-month high of $68.43. The company’s 50 day moving average price is $30.09 and its two-hundred day moving average price is $31.76. The firm has a market cap of $1.44 billion, a PE ratio of -30.40 and a beta of 0.77. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Principal Financial Group Inc. grew its holdings in shares of Immunocore by 25.0% during the 3rd quarter. Principal Financial Group Inc. now owns 546,318 shares of the company’s stock valued at $17,007,000 after purchasing an additional 109,206 shares during the last quarter. Assetmark Inc. boosted its position in Immunocore by 6.5% in the third quarter. Assetmark Inc. now owns 30,555 shares of the company’s stock valued at $951,000 after buying an additional 1,878 shares in the last quarter. Crossmark Global Holdings Inc. bought a new stake in shares of Immunocore during the third quarter worth $866,000. GSA Capital Partners LLP acquired a new position in shares of Immunocore during the third quarter worth $406,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in shares of Immunocore by 7.5% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 427,152 shares of the company’s stock valued at $13,297,000 after acquiring an additional 29,689 shares during the last quarter. Institutional investors and hedge funds own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.